Research focusing on older males, a subpopulation with a high prevalence of sarcopenia and associated adverse outcomes such as disability, is still insufficient, although a gradual and constant increase in circulating FSH also exists in men as aging (2) and the upregulation of FSH in males receiving androgen deprivation therapy promotes the development of several metabolic diseases such as metabolic syndrome, atherosclerotic cardiovascular disease, and insulin resistance (17). This evidence concerns the gene BRD2 and Other metabolic disease.